Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Using MRI scans to target biopsies is more effective at detecting prostate cancers that are likely to need treatment than standard ultrasound guided biopsies alone, according to research published on 7 August in JAMA Network Open. The research, led by the National Institute for Health Research (NIHR) and Universities of Bristol, Ottawa, Exeter and Oxford, combined the results from seven studies covering 2,582 patients.

The researchers found that the use of pre-biopsy MRI combined with targeted prostate biopsy was better than a biopsy alone in detecting prostate cancers that are likely to need treatment, despite the differences between the seven individual studies. Using pre-biopsy MRI led to fewer biopsy cores being taken per procedure, which in turn reduced side effects, and may potentially lead to avoiding biopsies for some men.

Taken together, this new evidence supports the use of pre-biopsy MRI in diagnostic pathways for suspected prostate cancer.

Read more (Nuffield Department of Surgical Sciences website) 

Similar stories

New research sheds light on how ultrasound could be used to treat psychiatric disorders

A new study in macaque monkeys has shed light on which parts of the brain support credit assignment processes (how the brain links outcomes with its decisions) and, for the first time, how low-intensity transcranial ultrasound stimulation (TUS) can modulate both brain activity and behaviours related to these decision-making and learning processes.

Rosalind Franklin Institute and Pharmacology announce strategic partnership in Next Generation Chemistry

The Rosalind Franklin Institute and the University of Oxford’s Department of Pharmacology have entered into a strategic partnership for Next Generation Chemistry.

New blood-based test is the first ever to simultaneously identify if a patient has cancer and if it has spread

A publication by University of Oxford researchers describes a new minimally invasive and inexpensive blood test that can identify cancer in patients with non-specific symptoms. The early success of this technology makes it the first blood-based test that not only detects cancer in this population but can simultaneously identify if a cancer has spread.

Alan Davidson Foundation supports ground-breaking Motor Neurone Disease research

A £210,000 donation from the Alan Davidson Foundation (ADF) has been made to the Nuffield Department of Clinical Neurosciences (NDCN) to advance the University’s world leading research into Motor Neurone Disease (MND). The funding will support a project manager for three years to deliver an innovative research project using the genetic causes of MND to develop approaches to early diagnosis and eventually, prevention of all forms of MND.

Research finds drug may benefit some patients hospitalised with COVID-19 pneumonia

A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.

Many Long COVID patients continue to experience symptoms one year after hospital discharge

People who were hospitalised with COVID-19 and continued to experience symptoms five months later, show limited further recovery one year after hospital discharge according to the latest results of a major national study.